Friday, 15 Nov 2019

You are here

Antibodies to 14-3-3η Found in Large Vessel Vasculitis

14-3-3η (eta) is a new test that may be useful in diagnosing patients with early rheumatoid arthritis. The test is 77% sensitive and 93% specific for RA and developers have found that antibodies against 14-3-3η may correlate with drug responsiveness.

Researchers from Cleveland Clinic examined aorta samples from 11 patients with large vessel vasculitis (LVV) and 11 controls and also examined sera from 23 LVV and matched controls and demonstrated that 78% of patients with large vessel vasculitis have antibodies to 14-3-3η.

14-3-3η is one isoform from a family of chaperone proteins involved in intracellular and extracellular signaling. 14-3-3η is not known to have a pathogenic role in RA but has also been shown to induce numerous proinflammatory mediators. The role of antibodies against 14-3-3η in the pathogenesis of vasculitis is unknown and merits further study.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.